Interleukin 6

New Study Explores Ways to Reduce Inflammation and Preserve Bone Health with Prunes

Retrieved on: 
Tuesday, December 12, 2023

ROSEVILLE, Calif., Dec. 12, 2023 /PRNewswire/ -- A new study published in The Journal of Nutrition shows daily consumption of prunes may reduce inflammation markers connected to bone signaling pathways and reduce the effects of bone loss among postmenopausal women.

Key Points: 
  • ROSEVILLE, Calif., Dec. 12, 2023 /PRNewswire/ -- A new study published in The Journal of Nutrition shows daily consumption of prunes may reduce inflammation markers connected to bone signaling pathways and reduce the effects of bone loss among postmenopausal women.
  • It's important to have a better understanding of how non-pharmacological approaches – like lifestyle and dietary choices—can also impact the progression and mitigation of bone loss."
  • This is an ancillary study of a larger, single-center, parallel-arm, 12-month randomized control trial1 (PRUNE study).
  • This investigation was completed by 183 participants who were split into three groups: control/no prunes (n=70), 50 grams/day prunes (n=67) and 100 grams/day prunes (n=46).

EnLiSense CCM To Advance IBD Care with Innovative Sweat Sensor Studies, Teams Up with Leading Clinicians

Retrieved on: 
Wednesday, October 4, 2023

Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.

Key Points: 
  • Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.
  • The IBD Aware system, a cornerstone of EnLiSense's innovative approach, continuously monitors key inflammatory biomarkers by gently resting on a patient’s skin sampling just nano-liters of passive sweat.
  • This non-invasive, wearable technology empowers both clinicians and patients with real-time data, facilitating personalized, data-driven, proactive management of chronic diseases like IBD.
  • Dr. Sriram Muthukumar, CEO of EnLiSense CCM, reflects on the early findings, stating, "The initial validation data is indeed very encouraging.

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer's Disease

Retrieved on: 
Wednesday, June 7, 2023

- Furthermore, Coya reports a case study of a patient in the COYA 301 trial who had pre-treatment and post-treatment Positron Emission Tomography (PET) brain scans to evaluate neuroinflammation.

Key Points: 
  • - Furthermore, Coya reports a case study of a patient in the COYA 301 trial who had pre-treatment and post-treatment Positron Emission Tomography (PET) brain scans to evaluate neuroinflammation.
  • Meaningful reductions in neuroinflammation were observed throughout the cerebral cortex including hippocampal regions following treatment with COYA 301, which correlated with improvement in cognitive function in this patient.
  • The patients were treated with five day-courses of COYA 301 for four monthly cycles and were followed for two months post-treatment.
  • "We believe these additional data further support our Treg-focused approach to develop safe and effective treatments for neurodegenerative diseases of high unmet need.

Innovative paper-like, battery-free, AI-enabled sensor for holistic wound monitoring

Retrieved on: 
Tuesday, June 27, 2023

SINGAPORE, June 27, 2023 /PRNewswire/ -- Timely and effective monitoring of wound healing status is critical to wound care and management.

Key Points: 
  • SINGAPORE, June 27, 2023 /PRNewswire/ -- Timely and effective monitoring of wound healing status is critical to wound care and management.
  • Wound infections are mostly diagnosed via swabbing followed by a bacteria culture which involves long waiting time and does not provide timely wound diagnosis.
  • These biomarkers were carefully selected to effectively assess wound inflammation, infection as well as the condition of the wound environment.
  • The bottom wound contact layer gently attaches the sensor patch to the skin and protects the wound bed from direct contact with the sensor panel, to minimise wound tissue disruptions.

Bioved Pharmaceuticals granted a US Patent for its oral, natural plant-based product, Artovid-20® for the treatment of Covid-19

Retrieved on: 
Tuesday, April 25, 2023

SAN JOSE, Calif., April 25, 2023 /PRNewswire/ -- Bioved Pharmaceuticals, Inc. is proud to announce that it has received a US Patent for its natural Ayurved based product, Artovid-20® Tablets for Covid-19.

Key Points: 
  • SAN JOSE, Calif., April 25, 2023 /PRNewswire/ -- Bioved Pharmaceuticals, Inc. is proud to announce that it has received a US Patent for its natural Ayurved based product, Artovid-20® Tablets for Covid-19.
  • "We are truly humbled with the grant of this patent", said Deepa Chitre, MD, Chief Executive Officer of Bioved.
  • She further added, "Thousands of US patents have been filed in the last three years for the diagnosis and treatment of Covid-19.
  • "The grant of the new patent demonstrates the outstanding innovation and strength of our research, product development and technology.

Bioved Pharmaceuticals granted a US Patent for its oral, natural plant-based product, Artovid-20® for the treatment of Covid-19

Retrieved on: 
Tuesday, April 25, 2023

SAN JOSE, Calif., April 25, 2023 /PRNewswire/ -- Bioved Pharmaceuticals, Inc. is proud to announce that it has received a US Patent for its natural Ayurved based product, Artovid-20® Tablets for Covid-19.

Key Points: 
  • SAN JOSE, Calif., April 25, 2023 /PRNewswire/ -- Bioved Pharmaceuticals, Inc. is proud to announce that it has received a US Patent for its natural Ayurved based product, Artovid-20® Tablets for Covid-19.
  • "We are truly humbled with the grant of this patent", said Deepa Chitre, MD, Chief Executive Officer of Bioved.
  • She further added, "Thousands of US patents have been filed in the last three years for the diagnosis and treatment of Covid-19.
  • "The grant of the new patent demonstrates the outstanding innovation and strength of our research, product development and technology.

NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost

Retrieved on: 
Wednesday, April 12, 2023

IBD AWARE is an inflammation tracker targeting key biomarkers associated with inflammatory bowel disease (IBD).

Key Points: 
  • IBD AWARE is an inflammation tracker targeting key biomarkers associated with inflammatory bowel disease (IBD).
  • Additional details about the IBD AWARE platform and how it works can be found at https://www.ibdwearable.com .
  • “IBD AWARE will provide patients and their clinicians with the real-time, actionable data they need to further quality of life outcomes.
  • The Crohn’s & Colitis Foundation launched IBD Ventures to accelerate the discovery and development of research-based products with the potential to address unmet needs of IBD patients.

Innovative Spinal Biomaterial Demonstrates Early Healing in Retrospective Study

Retrieved on: 
Thursday, September 8, 2022

that validates ZFUZE as the first homogenous new biomaterial introduced in more than 20 years.

Key Points: 
  • that validates ZFUZE as the first homogenous new biomaterial introduced in more than 20 years.
  • The ZFUZE retrospective study was conducted by Paul Kraemer, MD, at the Indiana Spine Group and consisted of 41 patients who underwent TLIF [define] single and double level lumbar interbody fusions.
  • "Maybe the most important thing about the study was there were no exclusion criteria," Dr. Kraemer said.
  • Medical Metrics LLC performed third-party radiographic fusion analysis via CT scan for 91.4% fusion rates at an early 8-month timepoint.

Ferring Announces New Collaboration for Development of Olamkicept

Retrieved on: 
Thursday, June 9, 2022

Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions.

Key Points: 
  • Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions.
  • Ferring had previously entered into a license agreement with I-Mab in 2016 that granted I-Mab exclusive rights to develop and commercialize olamkicept in Greater China and South Korea.
  • This new collaboration enables Ferring to invest in the development of olamkicept globally and provides an option for I-Mab to collaborate with Ferring in the future development of olamkicept at a pre-defined development milestone.
  • We are excited to expand our collaboration and advance olamkicept globally, as we continue to invest in our specialty area of gastroenterology.

Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows

Retrieved on: 
Thursday, May 19, 2022

(Credit: Feinstein Institutes)

Key Points: 
  • (Credit: Feinstein Institutes)
    The preclinical study published in the journal Molecular Medicine shows that famotidine, a histamine 2 receptor (H2R) antagonist, prevents cytokine storm in mice.
  • Investigators found that increased vagus nerve signals were why famotidine injections stopped cytokine storms.
  • By cutting the vagus nerve, known as a vagotomy, it prevented the ability of famotidine to stop the cytokine storms.
  • Now these new results point to a role of the vagus nerve inflammatory reflex in suppressing cytokine storm during COVID-19.